The first positron emission tomography (PET) tracers of tau pathology were developed almost a decade ago.1 These tracers have advanced our understanding of the role of tau pathology in aging and Alzheimer’s disease.2–5 However, several questions remain, including the spatial progression of the disease across the whole brain. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.